The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In this column, KFF President and CEO Drew Altman explores why the public's concerns about out-of-pocket health costs make health care affordability the health policy issue most likely to resonate with voters across the political spectrum.
In this column for The Wall Street Journal’s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it.
In his latest column for The Wall Street Journal‘s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it. All previous columns by Drew Altman are online.
As the coronavirus pandemic enters its eighth month, we are still facing uncertainty about what the long-term impact of the crisis will be for the health sector, and for patients. However, the extent to which costs grow, and how the burden is distributed across payers, programs, individuals, outcomes, and geography are still very much unknown. On Monday, October 19, KFF held a webinar on the outlook for the U.S. health system in light of the…
This analysis examines list prices for COVID-19 testing at the largest hospitals in every state and finds they range widely from $20 to $850. Federal law now requires private insurers to cover COVID-19 tests at no cost to the patient and provides funding for people without health insurance.
In this column for The Wall Street Journal's Think Tank, Drew Altman discusses why public concern over drug prices is the “tip of the iceberg” representing broader concerns about out-of-pocket health care costs.
This issue brief offers an early look into how competitive the health insurance exchanges (also called marketplaces) are under the Affordable Care Act in selected states. Through analysis of enrollment data released by seven states (California, Connecticut, Minnesota, New York, Nevada, Rhode Island, and Washington) this brief finds that exchange markets in California and New York are shaping up to be more competitive than their individual markets were in 2012 while those of Connecticut and…
This summarizes key provisions of the No Surprises Act, enacted in December 2020 to address the problem of unexpected medical bills, and issues that could arise during implementation ahead of its Jan. 1, 2022 effective date.
In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
This analysis finds that Medicare's negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.
© 2026 KFF